YBX1 and chronic myelogenous leukemia, BCR-ABL1 positive: Subsequently, loss of YBX1 via USP47 inhibition was shown to result in CML cell cycle arrest and apoptosis (Lei et al., 2021) proposing that these proteins could be used as targets to overcome TKIs resistance in CML.